Form 4: Xtant Medical Director Boosts Stake via DSU Award

Xtant Medical Holdings Director Stavros G. Vizirgianakis acquired 553,797 shares of common stock through a deferred stock unit award.

Summary

• Director Stavros G. Vizirgianakis acquired 553,797 shares of Xtant Medical Holdings, Inc. common stock on November 15, 2025.
• The acquisition was made through a Deferred Stock Unit (DSU) award granted under the company's Amended and Restated 2023 Equity Incentive Plan.
• These DSU shares will vest on November 15, 2026, contingent on Mr. Vizirgianakis remaining a director of Xtant Medical Holdings, Inc. through that date.
• The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement.
• Following this transaction, Mr. Vizirgianakis beneficially owns 7,515,570 shares, which includes 1,520,215 shares issuable upon settlement of previously granted deferred stock units.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, even if deferred, generally signals confidence in the company's future prospects and aligns management interests with shareholders. The deferred nature and vesting conditions are standard for such awards and do not indicate any immediate negative implications.

Positives

• Director Stavros G. Vizirgianakis increased his beneficial ownership in Xtant Medical Holdings, Inc. by 553,797 shares through a DSU award, signaling continued commitment.
• The DSU award aligns the director's interests with long-term shareholder value, as vesting is conditioned on continued service to the company.

Negatives

• The acquired shares are deferred stock units and do not immediately convert to common stock, with vesting scheduled for November 15, 2026, and settlement deferred further.

Risks

• The vesting of the 553,797 DSU shares is conditioned upon the reporting person remaining a director of Xtant Medical Holdings, Inc. through November 15, 2026.
• The settlement of the vested DSU shares is deferred to a later, unspecified date, meaning the director does not have immediate control or liquidity over these shares.

Future Outlook

The deferred vesting and settlement of the DSU award indicate a long-term retention strategy for key management, aligning director incentives with future company performance and strategic objectives.

Industry Context

This type of equity compensation, utilizing deferred stock units, is a common practice in the medical device and biotechnology sectors to incentivize and retain directors and executives, aligning their interests with long-term company growth and shareholder value.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) for director compensation is a standard practice across various industries, including medical technology. Companies like Medtronic (MDT) and Stryker (SYK) also utilize similar long-term equity incentive plans to compensate and retain their board members, linking their remuneration to the company's sustained performance and strategic objectives.
• The vesting schedule, conditioned on continued service, is typical for such awards, ensuring commitment from key personnel and promoting long-term strategic alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value due to increased beneficial ownership and deferred vesting, potentially fostering more stable governance.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• The 553,797 deferred stock units are scheduled to vest on November 15, 2026, provided the reporting person remains a director.
• Settlement of the vested DSU shares will occur at a later, unspecified date, pursuant to the award agreement terms.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation award to an existing director, which is a positive signal of alignment but does not provide new fundamental information to warrant a change in investment recommendation. The transaction is part of a standard incentive plan and does not reflect an open market purchase or sale based on new material information that would significantly alter the company's valuation or outlook.

Keywords

Xtant Medical Holdings, XTNT, Form 4, Insider Transaction, Director Stock Acquisition, Deferred Stock Units, Equity Incentive Plan, Corporate Governance